Erratum: Does saturable formation of gemcitabine triphosphate occur in patients? (Cancer Chemotherapy and Pharmacology (2008) 63 (55-64) DOI: 10.1007/s00280-008-0707-9);Does saturable formation of gemcitabine triphosphate occur in patients?

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 1, 2008, Pages 55-64

  Tham, Lai San ^a,b   Wang, Ling Zhi ^a   Soo, Ross A ^a   Lee, How Sung ^b   Lee, Soo Chin ^a   Goh, Boon Cher ^a   Holford, Nicholas H G ^c  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Gemcitabine; Gemcitabine triphosphate; Pharmacokinetics

Indexed keywords

2',2' DIFLUORODEOXYURIDINE; CARBOPLATIN; DRUG METABOLITE; GEMCITABINE; GEMCITABINE TRIPHOSPHATE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MICHAELIS MENTEN KINETICS; MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 53149117456     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2678-y     Document Type: Erratum

References (36)

1. JL Abbruzzese R Grunewald EA Weeks D Gravel T Adams B Nowak S Mineishi P Tarassoff W Satterlee MN Raber 1991 A phase I clinical, plasma, and cellular pharmacology study of gemcitabine J Clin Oncol 9 491 498
2. S Allerheiligen B Patel P Dhahir R Johnson B Hatcher B Cerimele T Rugg P Tarassoff A Dorr 1995 Population pharmacokinetic analyses: effect of age, gender, duration of infusion, body surface area on gemcitabine pharmacokinetics Pharm Res 12 Suppl 1 S327
3. AM Bergman VW van Ruiz Haperen G Veerman CM Kuiper GJ Peters 1996 Synergistic interaction between cisplatin and gemcitabine in vitro Clin Cancer Res 2 521 530
4. D Du Bois EF Du Bois 1916 A formula to estimate the approximate surface area if height, weight be known Arch Intern Med 17 863 871
5. SB Duffull MJ Dooley B Green SG Poole CM Kirkpatrick 2004 A standard weight descriptor for dose adjustment in the obese patient Clin Pharmacokinet 43 1167 1178
6. B Green SB Duffull 2004 What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 58 119 133
7. R Grunewald H Kantarjian MJ Keating J Abbruzzese P Tarassoff W Plunkett 1990 Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (Gemcitabine) administration in leukemia Cancer Res 50 6823 6826
8. R Grunewald JL Abbruzzese P Tarassoff W Plunkett 1991 Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine Cancer Chemother Pharmacol 27 258 262
9. R Grunewald H Kantarjian M Du K Faucher P Tarassoff W Plunkett 1992 Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study J Clin Oncol 10 406 413
10. V Heinemann YZ Xu S Chubb A Sen LW Hertel GB Grindey W Plunkett 1992 Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation Cancer Res 52 533 539
11. V Heinemann LW Hertel GB Grindey W Plunkett 1988 Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-beta-d-arabinofuranosylcytosine Cancer Res 48 4024 4031
12. LW Hertel GB Boder JS Kroin SM Rinzel GA Poore GC Todd GB Grindey 1990 Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro- 2′-deoxycytidine) Cancer Res 50 4417 4422
13. NH Holford 1996 A size standard for pharmacokinetics Clin Pharmacokinet 30 329 332
14. P Huang S Chubb LW Hertel GB Grindey W Plunkett 1991 Action of 2′,2′-difluorodeoxycytidine on DNA synthesis Cancer Res 51 6110 6117
15. S Janmahasatian SB Duffull S Ash LC Ward NM Byrne B Green 2005 Quantification of lean bodyweight Clin Pharmacokinet 44 1051 1065
16. MO Karlsson NE Jonsson CG Wiltse JR Wade 1998 Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients J Pharmacokinet Biopharm 26 2 207 246
17. JR Kroep G Giaccone DA Voorn EF Smit JH Beijnen H Rosing CJ van Moorsel CJ van Groeningen PE Postmus HM Pinedo GJ Peters 1999 Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer J Clin Oncol 17 2190 2197
18. BC Kuenen L Rosen EF Smit MR Parson M Levi R Ruijter H Huisman MA Kedde P Noordhuis WJ van der Vijgh GJ Peters GF Cropp P Scigalla K Hoekman HM Pinedo G Giaccone 2002 Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors J Clin Oncol 20 1657 1667
19. S Noble KL Goa 1997 Gemcitabine. A review of its pharmacology, clinical potential in non-small cell lung cancer and pancreatic cancer Drugs 54 447 472
20. GJ Peters M Clavel P Noordhuis GJ Geyssen AC Laan J Guastalla HT Edzes JB Vermorken 2007 Clinical phase I and pharmacology study of gemcitabine (2′, 2′-difluorodeoxycytidine) administered in a two-weekly schedule J Chemother 19 212 221
21. Peters RH (1983) The ecological implications of body size. Cambridge University Press, Cambridge
22. W Plunkett P Huang CE Searcy V Gandhi 1996 Gemcitabine: preclinical pharmacology and mechanisms of action Semin Oncol 23 Suppl 10 3 15
23. W Plunkett P Huang YZ Xu V Heinemann R Grunewald V Gandhi 1995 Gemcitabine: metabolism, mechanisms of action, and self-potentiation Semin Oncol 22 Suppl 11 3 10
24. M Sawyer MJ Ratain 2001 Body surface area as a determinant of pharmacokinetics and drug dosing Invest New Drugs 19 171 177
25. RA Soo LZ Wang LS Tham WP Yong M Boyer HL Lim HS Lee M Millward S Liang P Beale SC Lee BC Goh 2006 A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer Ann Oncol 52 153 158
26. AM Storniolo SR Allerheiligen HL Pearce 1997 Preclinical, pharmacologic, and phase I studies of gemcitabine Semin Oncol 24 Suppl 7 S7-2 S77
27. H Tang M Mayersohn 2005 A novel model for prediction of human drug clearance by allometric scaling Drug Metab Dispos 33 1297 1303
28. H Tang M Mayersohn 2005 Accuracy of allometrically predicted pharmacokinetic parameters in humans: role of species selection Drug Metab Dispos 33 1288 1293
29. M Tempero W Plunkett V Van Ruiz Haperen J Hainsworth H Hochster R Lenzi J Abbruzzese 2003 Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma J Clin Oncol 21 3402 3408
30. CJ van Moorsel JR Kroep HM Pinedo G Veerman DA Voorn PE Postmus JB Vermorken CJ van Groeningen WJ van der Vijgh GJ Peters 1999 Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors Ann Oncol 10 441 448
31. CJ van Moorsel HM Pinedo G Veerman AM Bergman CM Kuiper JB Vermorken WJ van der Vijgh GJ Peters 1999 Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines Br J Cancer 80 981 990
32. AP Venook MJ Egorin GL Rosner D Hollis S Mani M Hawkins J Byrd R Hohl D Budman NJ Meropol MJ Ratain 2000 Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: cancer and leukemia group B 9565 J Clin Oncol 18 2780 2787
33. LR Wang MZ Huang N Xu JZ Shentu J Liu J Cai 2005 Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer J Zhejiang Univ Sci B 6 446 450
34. LZ Wang BC Goh HS Lee P Noordhuis GJ Peters 2003 An expedient assay for determination of gemcitabine and its metabolite in human plasma using isocratic ion-pair reversed-phase high-performance liquid chromatography Ther Drug Monit 25 552 557
35. GB West JH Brown BJ Enquist 1997 A general model for the origin of allometric scaling laws in biology Science 276 122 126
36. L Zhang SL Beal LB Sheiner 2003 Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance J Pharmacokinet Pharmacodyn 30 387 404